1. |
Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity[J]. Ophthalmology, 2020, 127(4S): S84-96. DOI: 10.1016/j.ophtha.2020.01.034.
|
2. |
Hansen ED, Hartnett ME. A review of treatment for retinopathy of prematurity[J]. Expert Rev Ophthalmol, 2019, 14(2): 73-87. DOI: 10.1080/17469899.2019.1596026.
|
3. |
Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation[J]. Br J Ophthalmol, 2020, 104(5): 691-696. DOI: 10.1136/bjophthalmol-2019-314610.
|
4. |
Deng X, Cheng Y, Zhu XM, et al. Foveal structure changes in infants treated with anti-VEGF therapy or laser therapy guided by optical coherence tomography angiography for retinopathy of prematurity[J]. Int J Ophthalmol, 2022, 15(1): 106-112. DOI: 10.18240/ijo.2022.01.16.
|
5. |
Zhao J, Wu Z, Lam W, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity[J]. Br J Ophthalmol, 2020, 104(11): 1556-1560. DOI: 10.1136/bjophthalmol-2019-315520.
|
6. |
Kim KE, Park KH. Macular imaging by optical coherence tomography in the diagnosis and management of glaucoma[J]. Br J Ophthalmol, 2018, 102(6): 718-724. DOI: 10.1136/bjophthalmol-2017-310869.
|
7. |
Lim HB, Shin YI, Lee MW, et al. Longitudinal changes in the peripapillary retinal nerve fiber layer thickness of patients with type 2 diabetes[J]. JAMA Ophthalmol, 2019, 137(10): 1125-1132. DOI: 10.1001/jamaophthalmol.2019.2537.
|
8. |
中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Fundus Disease Group of Chinese Medical Association Ophthalmology Branch. Guidelines for screening retinopathy of premature infants in China(2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
|
9. |
Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial[J]. Arch Ophthalmol, 2003, 121(12): 1684-1694. DOI: 10.1001/archopht.121.12.1684.
|
10. |
Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors[J/OL]. PLoS One, 2008, 3(11): e3554[2008-11-03]. https://pubmed.ncbi.nlm.nih.gov/18978936/. DOI: 10.1371/journal.pone.0003554.
|
11. |
Marshall HN, Andrew NH, Hassall M, et al. Macular ganglion cell-inner plexiform layer loss precedes peripapillary retinal nerve fiber layer loss in glaucoma with lower intraocular pressure[J]. Ophthalmology, 2019, 126(8): 1119-1130. DOI: 10.1016/j.ophtha.2019.03.016.
|
12. |
Marlow N, Stahl A, Lepore D, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial[J]. Lancet Child Adolesc Health, 2021, 5(10): 698-707. DOI: 10.1016/S2352-4642(21)00195-4.
|
13. |
Kang HG, Choi EY, Byeon SH, et al. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety[J]. Br J Ophthalmol, 2019, 103(9): 1332-1336. DOI: 10.1136/bjophthalmol-2018-312272.
|
14. |
Lee YS, See LC, Chang SH, et al. Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment[J]. Am J Ophthalmol, 2018, 192: 20-30. DOI: 10.1016/j.ajo.2018.05.002.
|
15. |
Jeong JH, Choi YJ, Park KH, et al. Macular ganglion cell imaging study: covariate effects on the spectral domain optical coherence tomography for glaucoma diagnosis[J/OL]. PLoS One, 2016, 11(8): e0160448[2016-08-04]. https://pubmed.ncbi.nlm.nih.gov/27490718/. DOI: 10.1371/journal.pone.0160448.
|
16. |
Bae HW, Choi W, Hwang AR, et al. Effects of hypoxic preconditioning and vascular endothelial growth factor on the survival of isolated primary retinal ganglion cells[J]. Biomolecules, 2021, 11(3): 391. DOI: 10.3390/biom11030391.
|
17. |
Gangwe A, Agrawal D, Vinekar A, et al. Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: a survey among the members of Indian retinopathy of prematurity society[J]. Indian J Ophthalmol, 2021, 69(8): 2158-2163. DOI: 10.4103/ijo.IJO_200_21.
|
18. |
陈爽爽, 张琦, 任佳宁, 等. 早产儿视网膜病变治疗后黄斑发育研究现状及进展[J]. 中华眼底病杂志, 2021, 37(5): 394-398. DOI: 10.3760/cma.j.cn511434-20200114-00016.Chen SS, Zhang Q, Ren JN, et al. Recent advances in foveal development after treatment for retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2021, 37(5): 394-398. DOI: 10.3760/cma.j.cn511434-20200114-00016.
|
19. |
Young TL, Anthony DC, Pierce E, et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity[J]. J AAPOS, 1997, 1(2): 105-110. DOI: 10.1016/s1091-8531(97)90008-2.
|
20. |
Writing Committee for the Pediatric Eye Disease Investigator Group, Hartnett ME, Wallace DK, et al. Plasma levels of bevacizumab and vascular endothelial growth factor after low-dose bevacizumab treatment for retinopathy of prematurity in infants[J]. JAMA Ophthalmol, 2022, 140(4): 337-344. DOI: 10.1001/jamaophthalmol.2022.0030.
|
21. |
Kim US, Mahroo OA, Mollon JD, et al. Retinal ganglion cells-diversity of cell types and clinical relevance[J/OL]. Front Neurol, 2021, 12: 661938[2021-05-21]. https://pubmed.ncbi.nlm.nih.gov/34093409/. DOI: 10.3389/fneur.2021.661938.
|
22. |
Pueyo V, González I, Altemir I, et al. Microstructural changes in the retina related to prematurity[J]. Am J Ophthalmol, 2015, 159(4): 797-802. DOI: 10.1016/j.ajo.2014.12.015.
|
23. |
Tariq YM, Pai A, Li H, et al. Association of birth parameters with OCT measured macular and retinal nerve fiber layer thickness[J]. Invest Ophthalmol Vis Sci, 2011, 52(3): 1709-1715. DOI: 10.1167/iovs.10-6365.
|